Core Viewpoint - The article discusses the ongoing legal actions against Guangyuyuan (stock code: 600771) for false statements made between 2016 and 2021, leading to investor claims for compensation due to misleading financial disclosures [1][2]. Group 1: Legal Proceedings - The law firm Shanghai Jiucheng, represented by lawyer Xu Feng, has submitted multiple claims to the Taiyuan Intermediate People's Court regarding investor compensation for Guangyuyuan [1]. - The law firm continues to accept claims from other investors who have suffered losses due to the company's misleading financial practices [1]. Group 2: Regulatory Findings - On April 11, 2024, Guangyuyuan received an administrative penalty decision from the Shanxi Regulatory Bureau of the China Securities Regulatory Commission, confirming violations related to the company's financial reporting [1]. - The company was found to have misrepresented its "buyout sales" model in annual reports from 2016 to 2021, including improper revenue recognition and incorrect handling of sales expenses [1]. Group 3: Investor Compensation Eligibility - Investors who purchased Guangyuyuan stock between March 21, 2017, and December 29, 2023, and sold or continued to hold the stock after December 29, 2023, are eligible to initiate compensation claims [2]. - The law firm has a history of successfully representing investors in similar cases, with nearly 200 stocks resulting in victories or settlements [2].

Core Viewpoint - The company has received approval for the registration of Banxia Xiexin Decoction Granules, which will enhance its product portfolio in traditional Chinese medicine [1][4]. Group 1: Drug Information - The drug is named Banxia Xiexin Decoction Granules, in granule form, with a specification equivalent to 27.77g of herbal slices per bag [1]. - It is classified as a Category 3.1 traditional Chinese medicine, based on ancient classic prescriptions [1]. - The drug's approval number is Guoyao Zhunzi C20250017, and it is produced by Shanxi Guangyuyuan National Medicine Co., Ltd [1]. Group 2: Market Context - The prescription for Banxia Xiexin Decoction Granules originates from Zhang Zhongjing's "Shanghan Lun" and is included in the first batch of the National Administration of Traditional Chinese Medicine's classic formula directory [2]. - The market for gastrointestinal traditional Chinese medicine, including this product, is projected to reach a total sales amount of 10.615 billion yuan in 2024, reflecting a year-on-year increase of 1.01% [2]. - Currently, no other companies have obtained the drug registration certificate for Banxia Xiexin Decoction Granules in China [2]. Group 3: Company Investment - The company has invested a total of 9.0266 million yuan in the research and development of this drug to date [3]. Group 4: Impact on the Company - The approval of Banxia Xiexin Decoction Granules will diversify the company's traditional Chinese medicine product offerings and create synergies with existing core products [4].

证券日报网讯 12月23日，广誉远在互动平台回答投资者提问时表示，公司目前有海南知了有方医疗科 技有限责任公司、海南知了有方互联网医院有限公司、海南知了有方远程医疗中心有限公司三家子公司 注册地在海南，并实质性运营，均正常享受当地相关政策。公司作为百年老字号中药企业，会持续关注 相关政策变化，结合现有业务情况，及时研判规划，持续为公司长期发展注入动力。 （文章来源：证券日报） ...

Core Viewpoint - Guangyuyuan (600771.SH) announced that its subsidiary, Shanxi Guangyuyuan Traditional Chinese Medicine Co., Ltd., has received the drug registration certificate for Banxia Xiexin Decoction Granules from the National Medical Products Administration [1] Company Summary - The Banxia Xiexin Decoction Granules are derived from the ancient prescription in Zhang Zhongjing's "Shanghan Lun" and are included in the first batch of the "Directory of Classic Ancient Formulas" published by the National Administration of Traditional Chinese Medicine [1] - The product is indicated for balancing cold and heat, resolving phlegm, and is used for symptoms of phlegm syndrome characterized by fullness without pain, vomiting, bowel sounds, and slight yellow greasy tongue coating [1]

Core Viewpoint - Guangyuyuan (600771.SH) announced that its subsidiary, Shanxi Guangyuyuan Traditional Chinese Medicine Co., Ltd., received the drug registration certificate for Banxia Xiexin Decoction Granules from the National Medical Products Administration [1] Company Summary - The product, Banxia Xiexin Decoction Granules, is derived from the ancient text "Shanghan Lun" by Zhang Zhongjing from the Han Dynasty and is included in the first batch of the "Directory of Classic Ancient Formulas" published by the National Administration of Traditional Chinese Medicine [1] - The function and indication of the product are to harmonize cold and heat, resolve phlegm, and alleviate fullness, specifically for symptoms of phlegm syndrome characterized by fullness without pain, vomiting, bowel sounds, and slight yellow greasy tongue coating [1]

Core Viewpoint - Guangyuyuan (600771) is actively expanding its product distribution by entering the "Tao Xiaopang" supermarket with its health liquor products "Qingchun Xiaopao" and "Lanbaoshi" [1] Group 1 - The company's entry into "Tao Xiaopang" supermarket is part of its normal strategic planning for the liquor business [1] - This initiative aims to enhance interaction between products and consumers through diversified sales channels and consumption scenarios [1] - The company reports that production, sales, and supply are all operating normally, ensuring timely market demand fulfillment [1]

Group 1 - The core announcement is that Guangyuyuan's subsidiary, Shanxi Guangyuyuan Traditional Chinese Medicine Co., Ltd., has received the drug registration certificate for Banxia Xiexin Decoction Granules from the National Medical Products Administration [1] - The formula for Banxia Xiexin Decoction Granules is derived from the Han Dynasty text "Shanghan Lun" by Zhang Zhongjing, indicating its historical significance in traditional Chinese medicine [1] - The product is indicated for the treatment of symptoms related to the imbalance of cold and heat, specifically for phlegm accumulation and gastrointestinal discomfort, characterized by fullness without pain, vomiting, and diarrhea [1]

Core Viewpoint - Guangyuyuan (600771.SH) announced that its subsidiary, Shanxi Guangyuyuan Traditional Chinese Medicine Co., Ltd., received the drug registration certificate for Banxia Xiexin Decoction Granules from the National Medical Products Administration, enhancing its product portfolio in traditional Chinese medicine [1] Group 1 - The prescription for Banxia Xiexin Decoction Granules is derived from Zhang Zhongjing's "Shanghan Lun" from the Han Dynasty and is included in the first batch of the "Directory of Classic Ancient Formulas" published by the National Administration of Traditional Chinese Medicine [1] - The function and indications of Banxia Xiexin Decoction Granules include balancing cold and heat, dispersing masses, and alleviating fullness without pain, as well as symptoms such as vomiting, intestinal rumbling, and diarrhea [1] - The acquisition of the drug registration certificate for Banxia Xiexin Decoction Granules further enriches the company's range of traditional Chinese medicine products and will synergize with existing core products [1]

Group 1 - The core point of the article is that Guangyuyuan has received approval from the National Medical Products Administration for the registration of Banxia Xiexin Decoction granules, which is a significant development for the company [1] - Guangyuyuan's revenue composition for the first half of 2025 shows that the pharmaceutical industry accounts for 89.39%, while other businesses contribute 3.85%, and health wine accounts for 3.29% [1] - As of the report, Guangyuyuan's market capitalization stands at 8.9 billion yuan [1] Group 2 - The article also mentions that the real estate sector is facing challenges, with a notable 2 billion yuan debt maturing and ongoing negotiations for debt extension, alongside over 10 billion yuan in public debts due next year [1]

证券代码：600771 证券简称：广誉远 编号：临 2025-021 广誉远中药股份有限公司 关于控股子公司获得药品注册证书的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广誉远中药股份有限公司（以下简称"公司"）控股子公司山西广誉远国药 有限公司（以下简称"山西广誉远"）收到国家药品监督管理局核准签发的半夏泻心汤 颗粒的《药品注册证书》。现将相关情况公告如下： 一、药品基本信息 药品通用名称：半夏泻心汤颗粒 剂型：颗粒剂 规格：每袋相当于饮片 27.77g 注册分类：中药 3.1 类（按古代经典名方目录管理的中药复方制剂） 药品批准文号：国药准字 C20250017 药品注册证书编号：2025S03819 上市许可持有人：山西广誉远国药有限公司 米内网三大终端六大市场数据显示，半夏泻心汤颗粒所属的胃肠道类用药（中成药） 在 2024 年国内相应零售和医疗终端市场销售金额共计 106.15 亿元，同比上升 1.01%。 经检索国家药品监督管理局官方网站信息，截至目前，国内尚无企业取得半夏泻心汤颗 粒的药 ...